Moderna released full data on its closely watched cancer vaccine developed with Merck.

Novo released new evidence that its experimental CagriSema injection can improve upon the weight loss with its blockbuster GLP-1 obesity injection, Wegovy.

His comments come after Merck officially opened its new 120,000-square-foot research facility in the Greater Philadelphia area.

Pascal Soriot spoke exclusively with CNBC from the site of AstraZeneca’s new $1 billion R&D facility in Kendall Square in Cambridge, Massachusetts.

Eli Lilly and Novo are developing new amylin drugs that serve as another biological lever to pull in treating obesity and diabetes.

Lilly said it plans to start Phase 3 trials on the combo regimen adding its amylin drug eloralintide to tirzepatide at the end of the year. 

As Novo works to turn itself around, some analysts say Lilly has advantages that could help it maintain its position at the top of the obesity drug market. 

Vice President JD Vance’s White House Task Force to Eliminate Fraud estimates the action will save roughly $2.2 billion in taxpayer-funded subsidies.

They’re the latest metrics on how much the new Medicare coverage is expanding access to GLP-1 medicines since it launched in July.

Eli Lilly is trying to catch up in the GLP-1 pill market to Novo, which got a head start in the space.